Detail of the clinical trial
| Title of the trial | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin?s lymphoma (iNHL) - CHRONOS-4 |
|---|---|
| EudraCT number | 2015-001088-38 |
| Protocol number | BAY80-6946/17833 |
| Sponsor | Bayer HealthCare, AG, Kaiser-Wilhelm-Allee 10, 51368 Leverkusen, Germany |
| Indications | Oncology |
| Diagnosis | indolent non-Hodgkin?s lymphoma |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2015 |
| Date of approval by Institute (SÚKL) | 28.12.2015 |
| Date of approval by EC | 4.11.2015 |
| Date of initiation CT in ČR | 31.10.2017 |
| Date of ending CT in ČR | |
| Notice | |
| Sites | Fakultní nemocnice Královské Vinohrady, Interní hematologická klinika, Šrobárova 1150/50, 100 34 Praha 10 |
cz